Vitrolife introduces EmbryoScope+ and broadens time-lapse portfolio

Vitrolife is the market leader of time-lapse systems for use in assisted
reproduction. With the introduction of EmbryoScope+, the company can offer an
additional high quality time-lapse system for undisturbed culture and improved
selection of embryos. EmbryoScope+ has a large capacity in combination with a
small footprint, providing an efficient workflow and optimised usage of clinic
resources. The product will be introduced at the upcoming ESHRE conference next
week in Helsinki, Finland.
EmbryoScope+ is a time-lapse system with an integrated incubator. EmbryoScope+
builds on the same technology as the company´s world-wide used EmbryoScope, but
with a larger capacity for 15 patients with up to 16 embryos per patient in a
single instrument. The new system has a small footprint, which is an advantage
for labs where space is limited.

“The time-lapse market is growing and we believe that time-lapse has the
potential to become a standard tool in IVF treatments. With the introduction of
EmbryoScope+, we will make our time-lapse offer even more flexible”, says Thomas
Axelsson, CEO at Vitrolife.

Time-lapse technology enables the entire development of the embryo to be
studied, increasing the probability of choosing the embryo with the best chances
of leading to pregnancy. The use of time-lapse technology has been documented to
improve clinical outcomes.

Gothenburg, June 27, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on June
27, 2016 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

 Vitrolife has approximately 360 employees and the company's products are sold
in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary, Denmark and Germany. The Vitrolife share is listed on NASDAQ
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/